202828-84-0

Basic information

• Product Name: Pyridine, 2-(1-pentynyl)- (9CI)
• Synonyms: Pyridine, 2-(1-pentynyl)- (9CI)
• CAS NO: 202828-84-0
• Molecular Formula: C₁₀H₁₁N
• Molecular Weight: 145.20104
• Product Categories: PYRIDINE
• Mol File: 202828-84-0.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Pyridine, 2-(1-pentynyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Pyridine, 2-(1-pentynyl)- (9CI)(202828-84-0)
• EPA Substance Registry System: Pyridine, 2-(1-pentynyl)- (9CI)(202828-84-0)

Safety Data

• Hazardous Substances Data: 202828-84-0(Hazardous Substances Data)

Upstream product

• 5029-67-4 2-iodopyridine 
• 627-19-0 1-Pentyne 
• 109-04-6 2-bromo-pyridine 

Downstream Products

• 33354-97-1 2-n-pentylpiperidine 
• 1236144-82-3 tert-butyl 1-(4-(5-(4-propyl-5-(pyridin-2-yl)isoxazol-3-yl)-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylate 
• 1236144-41-4 1-(4-(5-(4-propyl-5-(pyridin-2-yl)isoxazol-3-yl)-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylic acid 
• 1403327-88-7 C₂₄H₂₃NO 

Relevant articles and documents

Preparation of monoalkylpiperidines via the mild hydrogenation of monoalkynylpyridines

Monoalkynylpyridines were prepared via a Sonogashira cross-coupling reaction between monoiodopyridines and alkynes. Mild hydrogenation of the obtained monoalkynylpyridines was then conducted to produce the corresponding monoalkylpiperidines in moderate to excellent yields. The hydrogenation reaction was carried out under H2 (1?atm) in the presence of 10?wt% Pd/C (5?eq) in either AcOH or MeOH at room temperature. The present mild method is therefore useful for the quick and easy preparation of monoalkylpiperidines.

An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer

A number of indole-3-glyoxylamides have previously been reported as tubulin polymerization inhibitors, although none has yet been successfully developed clinically. We report here a new series of related compounds, modified according to a strategy of redu

SUBSTITUTED OXADIAZOLE DERIVATIVES AS S1P AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES

[00180] Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein Q is or R1 is cycloalkyl, heteroaryl, or heterocyclyl, each optionally substituted with one to five substituents independently selected from C1 to C6 alkyl, C1 to C4 haloalkyl, -OR4, and/or halogen; and R2, R3, R4, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as vascular disease and autoimmune diseases.